Compare TG Therapeutics Inc (TGTX) vs Tesla, Inc. (TSLA) Price & Performance

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.

Tesla (TSLA) trades at $332.71, up 0.56% on the day, as the stock shows mixed signals with bearish technical indicators but recent positive earnings beats. The company faces declining profit margins (net income margin of 3.67% in 2025) despite steady revenue near $95B, while valuation ratios remain elevated with a P/E of 308. Recent news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV model.

Outlook remains bifurcated: long-term growth depends on AI and autonomy execution, but near-term risks include competitive pressures and high valuation. Analyst consensus price target of $393.87 suggests 18% upside, though technical weakness and earnings volatility warrant caution. Investment opportunity hinges on Tesla's pivot beyond automotive into robotics and energy.